CVM vs UTSI Comparison

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

UTStarcom Holdings Corp is engaged in providing telecommunication and networking products, solutions and services, focusing on optical networking, carrier-class packet optical, network synchronization, broadband products and a Software Defined Networking (SDN) platform optimized for AI networking infrastructure, mobile backhaul, metro aggregation, broadband access and value-added services. The Company operates through two segments: Equipment, which includes the sale of network infrastructure and application products such as broadband and wireless infrastructure technologies, and Services, which generates maximum revenue and provides support and operational services for equipment products. The Company generates maximum revenue from Japan.